journal article·2022-04Open access

Development of Receptor Binding Domain (RBD)‐Conjugated Nanoparticle Vaccines with Broad Neutralization against SARS‐CoV‐2 Delta and Other Variants

Ran Chen, Xiantao Zhang, Yaochang Yuan, Xiaohui Deng, Bolin Wu, Zhihui Xi, Guanwen Wang, Yingtong Lin, Rong Li, Xuemei Wang, Fan Zou, Liting Liang, Haiping Yan, Chaofeng Liang, Yuzhuang Li, Shijian Wu, Jieyi Deng, Mo Zhou, Xu Zhang, Congrong Li, Xiuqing Bu, Yi Peng, Changwen Ke, Kai Deng, Xin He, Yiwen Zhang, Zhenhai Zhang, Ting Pan, Hui Zhang

Advanced Science· Volume 9· Issue 11

Abstract

Abstract The SARS‐CoV‐2 Delta (B.1.617.2) strain is a variant of concern (VOC) that has become the dominant strain worldwide in 2021. Its transmission capacity is approximately twice that of the original strain, with a shorter incubation period and higher viral load during infection. Importantly, the breakthrough infections of the Delta variant have continued to emerge in the first‐generation vaccine recipients. There is thus an urgent need to develop a novel vaccine with SARS‐CoV‐2 variants as the major target. Here, receptor binding domain (RBD)‐conjugated nanoparticle vaccines targeting the Delta variant, as well as the early and Beta/Gamma strains, are developed. Under both a single‐dose and a prime‐boost strategy, these RBD‐conjugated nanoparticle vaccines induce the abundant neutralizing antibodies (NAbs) and significantly protect hACE2 mice from infection by the authentic SARS‐CoV‐2 Delta strain, as well as the early and Beta strains. Furthermore, the elicitation of the robust production of broader cross‐protective NAbs against almost all the notable SARS‐CoV‐2 variants including the Omicron variant in rhesus macaques by the third re‐boost with trivalent vaccines is found. These results suggest that RBD‐based monovalent or multivalent nanoparticle vaccines provide a promising second‐generation vaccine strategy for SARS‐CoV‐2 variants.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: SARS-CoV-2 and COVID-19 Research · SARS-CoV-2 detection and testing · COVID-19 Clinical Research Studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Institute of Human Virology Key Laboratory of Tropical Disease Control of Ministry Education Guangdong Engineering Research Center for Antimicrobial Agent and Immunotechnology Zhongshan School of Medicine Sun Yat‐sen University Guangzhou Guangdong 510080 China

Center for Infection and Immunity Study School of Medicine Shenzhen Campus of Sun Yat‐sen University Shenzhen Guangdong 518107 China

Guangdong Provincial People's Hospital Guangdong Academy of Medical Sciences Guangzhou Guangdong 510080 China

Qianyang Biomedical Research Institute Guangzhou Guangdong 510063 China

Department of Gastroenterology The Eight Affiliated Hospital Sun Yat‐sen University Shenzhen Guangdong 518033 China

Guangzhou National Laboratory Bio‐Island Guangzhou Guangdong 510320 China

BSL‐3 Laboratory Zhongshan School of Medicine Sun Yat‐sen University Guangzhou Guangdong 510080 China

Guangdong Provincial Center for Disease Control and Prevention Guangzhou 511430 China

Department of Immunology Zhongshan School of Medicine Sun Yat‐sen University Guangzhou 510080 China

Center for Precision Medicine Guangdong Provincial People's Hospital Guangdong Academy of Medical Sciences Guangzhou 510080 China

Funding

National Natural Science Foundation of China · Fundamental Research Funds for the Central Universities · Pearl River S and T Nova Program of Guangzhou

References (51)

Show source-provided references
1. 10.1016/S0140-6736(20)30185-910.1016/S0140-6736(20)30185-9 ↗
2. 10.1038/s41586-020-2012-710.1038/s41586-020-2012-7 ↗
3. 10.1056/NEJMoa200101710.1056/NEJMoa2001017 ↗
4. 10.1136/bmj.m103610.1136/bmj.m1036 ↗
5. Ortiz J. R. · Lancet · 2021 · 119
6. 10.1074/jbc.RA120.01487310.1074/jbc.RA120.014873 ↗
7. 10.1038/s41586-021-03361-110.1038/s41586-021-03361-1 ↗
8. 10.1016/j.cell.2020.11.02010.1016/j.cell.2020.11.020 ↗
9. 10.1136/bmj.m485710.1136/bmj.m4857 ↗
10. 10.1126/science.abg305510.1126/science.abg3055 ↗
11. 10.1038/s41586-021-03402-910.1038/s41586-021-03402-9 ↗
12. 10.1126/science.abd216110.1126/science.abd2161 ↗
13. 10.3390/microorganisms907154210.3390/microorganisms9071542 ↗
14. 10.1016/S0140-6736(21)02758-610.1016/S0140-6736(21)02758-6 ↗
15. 10.1001/jama.2021.229410.1001/jama.2021.2294 ↗
16. 10.1001/jama.2021.1418110.1001/jama.2021.14181 ↗
17. 10.1016/j.cmi.2021.05.02210.1016/j.cmi.2021.05.022 ↗
18. 10.1126/science.abd083110.1126/science.abd0831 ↗
19. 10.7554/eLife.6131210.7554/eLife.61312 ↗
20. 10.1016/j.chom.2021.03.00810.1016/j.chom.2021.03.008 ↗
21. 10.1016/j.jaut.2021.10271510.1016/j.jaut.2021.102715 ↗
22. 10.1001/jama.2021.1481110.1001/jama.2021.14811 ↗
23. 10.1016/j.cell.2021.06.02010.1016/j.cell.2021.06.020 ↗
24. 10.1038/s41591-021-01575-410.1038/s41591-021-01575-4 ↗
25. c)A. Y.Collier C. M.Brown K.McMahan J.Yu J.Liu C.Jacob‐Dolan A.Chandrashekar D.Tierney J. L.Ansel M.Rowe D.Sellers K.Ahmad R.Aguayo T.Anioke S.Gardner M.Siamatu L.Bermudez Rivera M. R.Hacker L. C.Madoff D. H.Barouch medRxiv 2021 https://doi.org/10.1101/2021.10.18.21265113.10.1101/2021.10.18.21265113 ↗
26. 10.1186/s12916-021-02103-410.1186/s12916-021-02103-4 ↗
27. 10.1056/NEJMoa210765910.1056/NEJMoa2107659 ↗
28. 10.1056/NEJMoa203538910.1056/NEJMoa2035389 ↗
29. 10.1056/NEJMoa203457710.1056/NEJMoa2034577 ↗
30. 10.1001/jama.2020.1554310.1001/jama.2020.15543 ↗
31. 10.1016/S1473-3099(20)30831-810.1016/S1473-3099(20)30831-8 ↗
32. 10.1126/science.abe623010.1126/science.abe6230 ↗
33. 10.1038/s41594-020-0469-610.1038/s41594-020-0469-6 ↗
34. 10.1038/s41586-020-2179-y10.1038/s41586-020-2179-y ↗
35. 10.1016/j.cell.2020.07.01210.1016/j.cell.2020.07.012 ↗
36. 10.7554/eLife.7065810.7554/eLife.70658 ↗
37. 10.1038/s41586-021-03398-210.1038/s41586-021-03398-2 ↗
38. 10.1056/NEJMoa210305510.1056/NEJMoa2103055 ↗
39. 10.1038/s41423-021-00641-810.1038/s41423-021-00641-8 ↗
40. 10.1038/s41586-021-03777-910.1038/s41586-021-03777-9 ↗
41. 10.1038/s41423-021-00776-810.1038/s41423-021-00776-8 ↗
42. Su D. · bioRxiv · 2021
43. 10.1016/j.vaccine.2021.11.00110.1016/j.vaccine.2021.11.001 ↗
44. 10.1038/d41586-021-00722-810.1038/d41586-021-00722-8 ↗
45. 10.1016/j.immuni.2020.11.01510.1016/j.immuni.2020.11.015 ↗
46. 10.1038/s41423-021-00736-210.1038/s41423-021-00736-2 ↗
47. 10.1016/j.immuni.2020.07.01910.1016/j.immuni.2020.07.019 ↗
48. 10.1056/NEJMc210497410.1056/NEJMc2104974 ↗
49. 10.1056/NEJMoa210889110.1056/NEJMoa2108891 ↗
50. 10.1002/jmv.2726110.1002/jmv.27261 ↗
51. 10.1038/s41565-020-0648-y10.1038/s41565-020-0648-y ↗